Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 over exp |
| Therapy | Cemiplimab |
| Indication/Tumor Type | penis squamous cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 over exp | penis squamous cell carcinoma | predicted - sensitive | Cemiplimab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with metastatic squamous cell carcinoma of the penis harboring CDKN2A R80* with high CD274 (PD-L1) expression (IHC>95%) previously treated with cisplatin-based chemotherapy and radiotherapy achieved a complete response to treatment with Libtayo (cemiplimab), and maintained the complete response six months after treatment cessation (PMID: 34267641). | 34267641 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34267641) | Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer. | Full reference... |